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A number of genes encoding neuropeptides are
expressed in the peripheral and central nervous
systems, in different endocrine organs, and in spe-
cialized cells distributed along the gastrointestinal
tract. Whether expression of the same neuropep-
tide gene in different tissues is regulated by similar
transcriptional mechanisms or by mechanisms
that differ in a cell-specific manner remains un-
clear. We report on promoter studies on the regu-
lation of the somatostatin gene in immortalized
neural precursor cells derived from developing rat
forebrain. Expression of the somatostatin gene in
these cells was determined by RT-PCR/Southern
blot analysis, by immunocytochemistry, and by
RIA. We show that in cerebrocortical and hip-
pocampal cells, expression of the somatostatin
gene is regulated by several negative and positive
DNA cis-regulatory elements located throughout
the promoter region. The somatostatin cAMP-
response element appears to play a prominent role
in neural somatostatin gene expression by acting
as a strong enhancer even in the absence of cAMP
stimulation. Site-directed mutagenesis followed by
transient transfection assays indicated that SMS-
TAAT1, SMS-TAAT2, and SMS-UE, three previously
identified homeodomain protein-binding regula-
tory elements that enhance transcription in pan-
creatic cells, act as repressors of transcription in
neural cells. Electrophoretic mobility shifts assays
indicate that those elements bind protein com-
plexes that differ between neural and pancreatic
cells. Our results support the notion that expres-
sion of the somatostatin gene in neural cells oc-
curs via transcriptional mechanisms that are dif-
ferent from those regulating expression of the
same gene in pancreatic cells. (Molecular Endocri-
nology 12: 1280–1293, 1998)
INTRODUCTION
Cells that synthesize polypeptide hormones acquire
their specific phenotypes during embryonic develop-
ment via molecular mechanisms that involve gene ac-
tivation and repression. Upon terminal differentiation,
different neuroendocrine cells express an ensemble of
transcriptional activator and repressor proteins that
interact on the promoter of target genes encoding
specific neuropeptide hormone precursors. These in-
teractions between a complex mixture of nuclear pro-
teins and their target DNA sequences, which appear to
follow a strict cell-specific combinatorial code tailored to
distinct cellular phenotypes, modulate appropriate levels
of cell-specific expression of each neuropeptide-encod-
ing gene in basal conditions and in response to changes
in the extracellular environment.
A particular neuropeptide-encoding gene may be
expressed throughout the organism in a variety of
tissues and cell types with different embryonic origins
(1). Many of them are expressed in the central nervous
system as well as in peripheral tissues, including the
gastrointestinal tract and specific endocrine organs.
However, whether cell-specific expression of a neu-
ropeptide gene in ontogenically different tissues is
regulated by similar or identical mechanisms remains
unclear.
Somatostatin is a neuropeptide hormone whose ex-
pression is restricted to cells in the peripheral and
central nervous systems, as well as to parafollicular
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cells of the thyroid gland, D cells of the digestive tract,
and D cells of the pancreatic islets of Langerhans (2).
Among these tissues, the endocrine pancreas has pro-
vided an informative model with which to study tran-
scriptional mechanisms of control of cell-specific so-
matostatin gene expression, due, in no small part, to
the availability of a number of pancreatic cell lines that
recapitulate phenotypic features of pancreatic islet
cells. Using such cell lines, previous studies by several
investigators have shown that pancreatic D cell-
specific expression of the somatostatin gene is the
consequence of the binding of a number of nuclear
proteins to well defined DNA cis-regulatory elements
located in its promoter region. These elements include
a cAMP-response element (CRE) located in relative
proximity to the TATA box (3–6), several tissue-
specific enhancers that provide binding sites for ho-
meodomain transcription factors (7–9), and several si-
lencer elements (10).
In the central nervous system, somatostatin was
first discovered in the hypothalamus and was found
subsequently to be widely distributed in other areas,
including hippocampus, cerebral cortex, and basal
forebrain, where it appears to serve as an inhibitory
neurotransmitter released from small interneurons
(11). In the rat, the first somatostatin-positive cells in
the forebrain appear at embryonic day 14 (E14) (12,
13). In some cells, this expression is transient, whereas
in others it is maintained in the adult brain, and thus it
has been proposed that in addition to its role as a
neurotransmitter, somatostatin may have trophic ef-
fects on target cells during brain development (14–16).
The transcriptional mechanisms that control cell-
specific somatostatin gene expression in the central
nervous system are unknown. In the present study, we
report on the establishment of conditionally immortal-
ized somatostatin producing cell lines derived from rat
embryonic brain. By using transient transfection as-
says, DNA mutagenesis, and DNA-protein binding as-
says, we show that expression of the somatostatin
gene in neural cells is regulated by the strong positive
activity of the CRE, which is under the influence of at
least three negative acting upstream elements. A func-
tional analysis of the somatostatin gene promoter in
neural cells indicated that these negative-acting ele-
ments correspond to previously described pancreatic
enhancers that bind homeodomain transcription
factors.
RESULTS
Establishment of Somatostatin-Producing
Forebrain-Derived Immortalized Cells
Two regions of the forebrain, the cerebral cortex and
the hippocampus, were chosen as a source of cells for
immortalization because somatostatin is expressed in
cells in these regions during development and in the
adult brain. Cells growing as primary cultures from
embryonic cerebral cortex and hippocampus were in-
fected with a recombinant retrovirus carrying genes
encoding tsA58/U19 (17, 18), a temperature-sensitive
mutant of the Simian Virus 40 large-T antigen (SV40T),
and aminoglycoside phosphotransferase to confer re-
sistance of the neomycin homolog G418. A total of 15
clonal cell lines were derived from G418-resistant col-
onies from hippocampal cultures, and 38 clonal cell
lines were derived from cultured cerebrocortical cells.
A subset of these cell lines was screened for expres-
sion of the somatostatin gene by RT-PCR. One cell line
derived from embryonic hippocampus (RH1.C4 cells)
and one derived from embryonic cerebral cortex
(RC2.E10) exhibited levels of somatostatin transcripts
comparable to those observed in control pancreatic
islet D-like RIN-1027-B2 cells (Fig. 1A). At least three
other cortical cell lines were found to express soma-
tostatin, albeit at relatively lower levels (Fig. 1A).
Hippocampal RH1.C4 and cerebrocortical RC2.E10
cells were expanded and have been propagated con-
tinuously for more than 2 yr (.70 passages) with no
apparent change in phenotype. Both cell types prolif-
erate in a serum-dependent manner and exhibit fea-
tures of neural precursors that can differentiate under
specific culture conditions, details of which have been
previously reported (19) and will be published else-
where. Somatostatin expression in these two cell
types was confirmed by immunocytochemistry (Fig. 2).
Somatostatin content of RH1.C4 and RC2.E10 cells,
as determined by RIA (three determinations for each
cell type in duplicate), was 340 6 20 fmol/mg and
260 6 60 fmol/mg, respectively.
Since we used a temperature-sensitive mutant
SV40T (17, 18), we were able to determine whether the
presence of SV40T affects somatostatin gene expres-
sion. For this purpose, RC2.E10 cells were incubated
at the nonpermissive temperature (39 C) for 24 h, and
degradation of SV40T was confirmed both by Western
immunoblotting (Fig. 1B) and immunocytochemically
(not shown). Levels of somatostatin message in cells
incubated at 39 C were similar to those in cells incu-
bated at the permissive temperature (33 C), indicating
that the presence of SV40T does not significantly af-
fect somatostatin gene expression (Fig. 1C).
Positive- and Negative-Acting Promoter Elements
Regulate Neural Cell Expression of the
Somatostatin Gene
To obtain information about the activity of the soma-
tostatin gene promoter region in neural cells, we car-
ried out transient transfection assays in hippocampal
RH1.C4 cells and in cortical RC2.E10 cells. Initially, we
used the plasmid SMS900, a chloramphenicol acetyl-
transferase (CAT) reporter plasmid that contains a
fragment of the somatostatin gene spanning nucleo-
tides 2900 to 154 (4, 5), and compared its activity to
that of a Rous sarcoma virus enhancer-driven CAT
reporter (RSVCAT). Figure 3B shows that the level of
expression of SMS900 CAT in RH1.C4 cells was sim-
Somatostatin Gene Expression in Neural Cells 1281
 by on May 10, 2010 mend.endojournals.orgDownloaded from 
ilar to that determined in pancreatic RIN-1027-B2 cells
(5), whereas SMS900 CAT expression in RC2.E10 cells
was lower.
To determine the approximate boundaries of tran-
scriptional control regions of the somatostatin gene
promoter that contain positive or negative DNA cis-
regulatory elements, we transfected somatostatin CAT
reporter plasmids generated by sequential 59-dele-
tions of the fragment in SMS900 (4, 5). We found that
a deletion to nucleotide 2750 results in a significant
decrease in CAT activity in both RH1.C4 and RC2.E10
cells (Fig. 3C), suggesting the presence of enhancer
elements upstream of that position. A more extensive
deletion to nucleotide 2550 resulted in values of CAT
activity that were not significantly different from those
obtained with SMS900, thus suggesting the presence
of negative regulatory elements located between nu-
cleotides 2750 and 2550. The activity of the plasmids
with deletions to nucleotides 2425 and 2345 was
significantly lower than that of SMS900, although in
RC2.E10 cells the level of expression of SMS425 was
relatively higher than in RH1.C4 cells (Fig. 3C). None-
theless, the decreased CAT activities exhibited by
both plasmids indicated the removal of positive regu-
latory elements located between nucleotides 2550
and 2345. A further deletion to nucleotide 2250 re-
stored CAT activity to levels not significantly different
from those of SMS900 in RH1.C4 cells, but in RC2.E10
cells this deletion resulted in a significant increase in
CAT activity (.2-fold relative to SMS900), indicating
the existence of repressor elements between nucleo-
tides 2345 and 2250. Additional deletions resulted in
higher levels of expression in both cell types, but the
observed increases in CAT activities were higher in
RC2.E10 than in RH1.C4 cells. Thus, relative to
SMS900, the levels of expression of SMS120, which
contains a previously identified somatostatin up-
stream element (SMS-UE) and a CRE (5), were ap-
proximately 2- to 3-fold and 8-fold higher in RH1.C4
and RC2.E10 cells, respectively. Finally, removal of the
SMS-UE by a deletion to nucleotide 265, leaving in-
tact the CRE, resulted in a further 5-fold and 15-fold
increase in CAT activity in RH1.C4 and RC2.E10 cells,
respectively. This increase in CAT activity was depen-
dent on the presence of the CRE, as indicated by the
observation that its removal by a deletion to nucle-
otide 242, retaining a minimal promoter that con-
tains the TATA box, resulted in low levels of CAT
activity (Fig. 3C).
Requirement of the CRE for Promoter Activity in
RC2.E10 Cells
The above experiments suggest that the CRE plays a
prominent role as a DNA cis-regulatory element me-
diating somatostatin gene expression in neural cells.
Indeed, it appears that somatostatin gene transcrip-
tion is potently activated by this element, and that its
activity is down-regulated by upstream negative mod-
ulatory elements. To examine this notion in detail, we
chose to focus our attention on cortex-derived
RC2.E10 cells, because the CAT activity generated by
SMS65 in these cells was significantly higher than in
hippocampus-derived RH1.C4 cells, indicating that
the CRE is more potent in the former than in the latter
cell type. In addition, our 59-deletion analysis sug-
gested that in RC2.E10 cells relatively potent repres-
sor elements may be needed to counteract the activity
generated by the CRE.
We introduced an internal four-base deletion in
SMS900 that disrupts the CRE motif (from TGACGTCA
to TG—-CA), and determined the CAT activity generated
by the resulting plasmid, SMS900DCRE, after transient
transfection into RC2.E10 cells. These experiments indi-
cated that the integrity of the CRE is required for soma-
tostatin promoter function in neural cells, because dis-
Fig. 1. Somatostatin Gene Expression in Cells Derived from
Rat Embryonic Hippocampus and Cerebral Cortex
A, Somatostatin message detected by reverse transcrip-
tase-PCR/Southern blot hybridization was found expressed
in one (RH1.C4) of five hippocampal cell lines tested (left
panel) and in several cerebrocortical cell lines (right panel). Of
these, the highest levels, as compared with those of pancre-
atic islet RIN-1027-B2 cells (RIN-B2, right-most lane), were
observed in RC2.E10 cells. B, Western immunoblot showing
temperature-dependent degradation of SV40T (top panel) in
hippocampal RH1.C4 cells (C4) and in cerebrocortical
RC2.E10 cells (E10). As a control, a shift to the nonpermissive
temperature did not affect immunoreactive levels of CREB
(bottom panel). C, Somatostatin message detected by re-
verse transcriptase-PCR/Southern blot hybridization in
RH1.C4 (C4) and RC2.E10 (E10) cells incubated at either 33
C or 39 C.
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ruption of the CRE resulted in reduced CAT activities
indistinguishable from background levels (Fig. 3A). In
addition, these results lend additional support to the
hypothesis that the resulting transcriptional activity im-
parted by the full-length promoter is the result of the
activity of repressor elements that counteract the tran-
scriptional effect of positive regulatory elements that re-
quire the presence of an intact CRE.
DNA Elements Containing “TAAT” Motifs in the
Somatostatin Promoter Act as Negative
Modulators of Transcription in Neural Cells
To search for additional promoter elements located
upstream from the CRE that regulate somatostatin
gene expression in neural cells, we studied promoter
elements that have been shown previously to regulate
somatostatin gene expression via binding of home-
odomain transcription factors in pancreatic cells.
The SMS-UE (nucleotides 2114 to 278) contains a
so-called domain B (UE-B) with a core TAAT motif that
binds homeodomain transcription factors in pancre-
atic cells (5, 7, 8, 20). Two other homeodomain-
binding regulatory elements in the somatostatin gene
promoter, SMS-TAAT1 and SMS-TAAT2, located at
positions 2449 to 2445 and 2295 to 2292, respec-
tively, have been described (8, 20). Inspection of the
DNA sequence of the somatostatin promoter revealed
the existence of a previously unidentified TAAT motif
located between nucleotides 2368 and 2365, which
we named SMS-TAAT3. To determine whether these
elements regulate the expression of the somatostatin
gene in neural cells, we carried out transient transfec-
tions in RC2.E10 cells and tested CAT activities of
plasmids in which the TAAT motif of each one of them
had been altered by site-directed mutagenesis. Re-
duced binding of nuclear proteins from RC2.E10 cells
to these mutated sequences was confirmed by elec-
trophoretic mobility shift assay (EMSA) (data not
shown).
Disruption of each one of the aforementioned
TAAT motifs independently resulted in increases in
CAT activity relative to the wild-type SMS900 (Fig.
4A). The highest increase (;4-fold) was found with
plasmid SMS900T1M (SMS-TAAT1 mutant), fol-
lowed by both SMS900T2M (SMS-TAAT2 mutant)
and SMS900UEBM (SMS-UE-B mutant). Disruption
of SMS-TAAT3 (plasmid SMS900T3M) only resulted
in a modest (,2-fold) increase in CAT activity. Mu-
tations of more than one of these motifs simulta-
neously, in different combinations, did not result in
further increases in CAT activity (data not shown).
These experiments suggest that SMS-TAAT1, SMS-
TAAT2, and SMS-UE-B (and to a lesser extent SMS-
TAAT3) negatively regulate transcription of the soma-
Fig. 2. Immunocytochemistry of Somatostatin in Hippocampus-derived RH1.C4 Cells (A and B) or Cerebrocortex-Derived
RC2.E10 Cells (C and D)
Control cells were incubated with normal rabbit serum in place of the somatostatin-specific antiserum (1:500). Nuclei were
stained with hematoxylin.
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tostatin promoter in neural cells, an effect opposite to
that previously described in pancreatic cells (5, 7, 8,
20). However, mutation of each one of them alone or in
combination did not result in levels of CAT activity as
high as those generated by SMS65, which contains
the CRE as the only active cis-acting element (see Fig.
3C for comparison) suggesting that either they are
weak repressors, or that additional non-TAAT-con-
taining negative modulatory elements exist at different
locations on the somatostatin promoter. To gain in-
sight into which one of these possibilities is more likely
to be correct, we tested the relative strength of each
one of these elements in isolation in suppressing CRE-
driven transcription. To this end, we constructed plas-
mids by inserting synthetic oligonucleotides corre-
sponding to SMS-TAAT1, SMS-TAAT2, or SMS-
TAAT3 immediately upstream from the CRE in the
plasmid SMS65 and carried out transient transfections
to compare the CAT activity generated by these plas-
mids with that generated by SMS65 in RC2.E10 cells.
Initially, we determined that a 4-bp deletion in SMS65
that disrupts the CRE motif results in a significant
reduction in CAT activity (Fig. 4B).
Placing either SMS-TAAT1 or SMS-TAAT2 immedi-
ately upstream from the CRE resulted in a marked
decrease in SMS65 CAT activity (Fig. 4B). The de-
crease observed with TAAT1-SMS65 was more pro-
nounced than that observed with TAAT2-SMS65, re-
sulting in levels of CAT expression barely above
background levels. In contrast, SMS-TAAT3 did not
significantly reduce levels of SMS65 CAT expression.
Thus, SMS-TAAT1 and SMS-TAAT2, but not SMS-
TAAT3, appear to be relatively strong repressors of
CRE-dependent transcription. In an analogous man-
ner, our 59-deletion experiments indicated that
SMS-UE-B can also repress CRE-mediated tran-
scription (compare the activities of SMS120 and
SMS65 in Fig. 3C).
Binding of Nuclear Proteins to TAAT-Containing
Elements
The activities of SMS-TAAT1, SMS-TAAT2, and SMS-
UE-B as DNA cis-acting elements that control soma-
tostatin gene expression have been previously studied
in pancreatic cells, where they appear to act as pos-
itive regulatory elements. Because our studies indicate
that those elements act as transcriptional repressors
in neural cells, it was of interest to determine whether
the complement of nuclear proteins that bind to them
is different in neural and in pancreatic cells. For that
purpose, we carried out EMSA with synthetic oligonu-
cleotides corresponding to SMS-TAAT1, SMS-TAAT2,
SMS-TAAT3, or SMS-UE-B, using nuclear extracts
from cortical RC2.E10 cells or from pancreatic RIN-
1027-B2 cells. When the SMS-TAAT1 probe was
used, three distinct DNA-protein complexes were
found with nuclear extracts from RC2.E10 cells (Fig.
5). Specificity of these complexes was determined by
competition with unlabeled SMS-TAAT1 oligonucleo-
tide added in excess to the binding reaction. Addition
of an oligonucleotide of unrelated sequence failed to
compete. A similar pattern was found when SMS-
TAAT2 or SMS-TAAT3 probes were used, with the
exception that an additional complex with relatively
fast electrophoretic mobility (complex 4) was found
with SMS-TAAT3 (Fig. 5).
Fig. 3. Somatostatin Promoter Activity in Neural Cells De-
rived from Embryonic Rat Forebrain
A, Schematic depiction of the rat somatostatin/CAT fusion
gene SMS900. Numbers on top represent nucleotide posi-
tions relative to the transcriptional start site, used to generate
59-deletion constructs. The relative positions of the regulatory
elements SMS-TAAT1 (T1), SMS-TAAT2 (T2), SMS-TAAT3
(T3), proximal silencers 1 and 2 (PS, Ref. 10), SMS-UE (UE),
and CRE are indicated. B, Relative activity of the SMS900
CAT reporter gene transiently transfected in somatostatin-
producing cell lines derived from rat embryonic cerebral cor-
tex (RC2.E10), rat embryonic hippocampus (RH1.C4), or rat
pancreatic islet RIN-1027-B2 (RIN-B2). Values are expressed
as percentages of the activities elicited by the Rous sarcoma
virus/CAT fusion gene transfected in the same experiments.
C, Relative CAT activities obtained after transient transfec-
tions of somatostatin-CAT 59-deletion plasmids in RH1.C4 or
RC2.E10 cells. Values are expressed as percentages of the
activities elicited by SMS900 CAT transfected in the same
experiments. Note the different scale on the right panel to
show higher values of CAT activity obtained with plasmids
deleted to positions 2120 and 265.
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When nuclear extracts from pancreatic RIN-
1027-B2 cells were used, clear differences in the pat-
tern of retarded bands generated with each probe
were observed (Fig. 5). Binding of nuclear proteins to
the SMS-TAAT1 probe resulted in the generation of
two relatively strong complexes of similar intensities
that appear to migrate at the levels of complexes 1 and
3, respectively, detected with nuclear extracts of
RC2.E10 cells. Complex 3 generated with nuclear ex-
tracts of RIN-1027-B2 cells was found to consist of
two distinct bands that migrate electrophoretically in
close proximity. Another difference detected was that
the intensity of complex 2 from pancreatic cell nuclear
extracts was consistently weaker than its counterpart
from neural cell nuclear extracts. In addition, a doublet
of relatively low intensity and slow electrophoretic mo-
bility (Fig. 5, arrow) was detected with RIN-1027-B2
nuclear extracts but not with RC2.E10 nuclear ex-
tracts. Similar differences were found when SMS-
TAAT2 and SMS-TAAT3 were used, with the exception
that when the SMS-TAAT3 probe was used with nu-
clear extracts of RIN-1027-B2 cells, no complex was
found migrating slower than complex 1. SMS-TAAT3-
specific complex 4 was found in both neural and pan-
creatic cell nuclear extracts (Fig. 5).
When the UE-B probe was used, three closely mi-
grating bands with relatively slow electrophoretic mo-
bilities were detected with nuclear extracts of RC2.E10
cells, with the fastest one exhibiting the strongest
intensity (Fig. 5). In contrast, only two complexes were
detected when RIN-1027-B2 nuclear extracts were
used, and in this case the strongest intensity was
exhibited by the band with slower electrophoretic
mobility.
To investigate the presence of proteins that recog-
nize somatostatin TAAT sites in the developing rat
brain, we prepared nuclear extracts from the forebrain
of E17 fetuses removed from timed-pregnant rats and
assessed DNA-protein binding by EMSA. We found
that the pattern of bands generated by SMS-TAAT1
and SMS-TAAT2, and SMS-UE-B in extracts of E17
forebrains shows similarities with those found with
nuclear extracts of RC2.E10 cells. For SMS-TAAT1
and SMS-TAAT2, we detected complexes 1, 2, and 3,
Fig. 4. Repressor Activity of TAAT-Containing Elements of the Somatostatin Promoter in RC2.E10 Cells
A, Top panel, schematic representation of wild-type (SMS900) and mutated somatostatin CAT reporter constructs used to
transfect embryonic cerebral cortex-derived RC2.E10 cells. TAAT-containing elements are depicted as open boxes, and their
mutated versions are indicated as crossed-out boxes. The elements are: T1, SMS-TAAT1; T2, SMS-TAAT2; T3, SMS-TAAT3; and
UE, SMS-UE-B. Bottom panel, relative CAT activities of the above plasmids observed after transfections in RC2.E10 cells. Values
are expressed as percentages of the activities elicited by wild-type SMS900 CAT. B, Effects of SMS-TAAT1 (T1), SMS-TAAT2 (T2),
or SMS-TAAT3 (T3) on basal CRE-dependent transcription. SMS65 contains a TATA box and a CRE, which is deleted in
SMS65DCRE (5). Values are expressed as percentages of the CAT activities elicited by SMS65.
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which were found to comigrate with the corresponding
ones observed with nuclear extracts of RC2.E10 cells
(Fig. 6A). As shown in Fig. 6A, specificity of binding of
these complexes to DNA was confirmed by competi-
tion with unlabeled oligonucleotides. When we used
the SMS-UE-B probe, three closely migrating com-
plexes were found in embryonic forebrain extracts,
with similar electrophoretic mobilities to those ob-
served with RC2.E10 nuclear extracts (Fig. 6B). Spec-
ificity of complexes from embryonic forebrain bound
to SMS-UE-B was confirmed by competition experi-
ments with nonlabeled oligonucleotides (not shown).
Thus, these experiments support the notion that in the
developing brain in vivo, somatostatin gene-regulatory
elements are recognized by similar proteins to those
found in cortex-derived RC2.E10 cells.
We also investigated whether SMS-TAAT1, SMS-
TAAT2, and SMS-UE-B bind homeodomain transcrip-
tion factors in neural cells, as has been described to be
the case in pancreatic cells (8, 9, 20). For that purpose,
we carried out EMSA in the presence of an antiserum
(Hm-66) raised against IDX-1 (8), an antennapedia-like
homeoprotein expressed in pancreas and duodenum
that regulates somatostatin gene transcription in pan-
creatic cells by binding to those elements (8, 9, 20).
This antiserum recognizes the homeodomains of re-
lated transcription factors (J. Habener, personal com-
munication), and therefore any perturbation in the
banding pattern observed in its presence would be
indicative of the binding of homeodomain-type tran-
scription factors to the corresponding oligonucleo-
tides. Figure 6B shows that the presence of this anti-
serum in the binding reaction resulted in the
disappearance of the upper band detected with the
SMS-UE-B probe, using either RC2.E10 or E17 fore-
brain nuclear extracts. Addition of the antiserum to the
binding reaction did not result in any modification of
the band pattern observed with SMS-TAAT1 or SMS-
TAAT2. Thus, these experiments suggest that SMS-
UE-B binds a homeodomain-type protein present in
neural cells.
Stimulation of Somatostatin Gene Transcription
by cAMP
Previous studies carried out in pancreatic cells have
provided evidence in support of synergistic interac-
tions between CRE-binding proteins and proteins that
bind to SMS-UE or TAAT elements (5, 21). However,
those studies were carried out in pancreatic cell lines
in which somatostatin gene transcription is not stim-
ulated by cAMP, likely due to a defect in the phos-
phorylation of nuclear factor CRE-binding protein
(CREB) (6). Therefore, we investigated whether regu-
latory TAAT elements participate in the modulation of
the transcriptional responses induced by cAMP in
neural cells. To this end, we transfected RC2.E10 cells
with either SMS900 or with similar plasmids, in which
each one of the TAAT elements had been individually
mutated, and treated them with the cAMP analog
8-Br-cAMP (1 mM). Treatment of RC2.E10 cells with
8-Br-cAMP for 16 h resulted in an 8-fold increase in
the CAT activity generated by SMS900 (Fig. 7). That
response was abolished by deletion of four bases in
Fig. 5. EMSA with Nuclear Extracts of Somatostatin-Producing Cells Derived from Embryonic Cerebral Cortex (RC2.E10) or
Pancreatic Islets (RIN-B2)
Oligonucleotide probes used in each assay are indicated at the bottom. Nuclear extracts were incubated in the absence (2)
or presence of competing oligonucleotides [10-, 50- or 100-fold molar excess (103, 503, or 1003, respectively)] of identical
probe sequence, or in the presence of a nonspecific competing (NSC) oligonucleotide of unrelated sequence used in a 100-fold
molar excess. Complexes numbered 1–4 are described and discussed in the text. Arrows indicate protein-DNA complexes of slow
electrophoretic mobility observed in pancreatic, but not in neural, extracts.
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the CRE (Fig. 7). The magnitude of the response of
SMS900 to 8-Br-cAMP stimulation was blunted by
mutations in SMS-TAAT1 (4.9-fold), SMS-TAAT2 (3.4-
fold), or SMS-UE-B (5.1-fold) but not significantly al-
tered by mutations in SMS-TAAT3 (7.7-fold).
One possible interpretation of these results is that
mutations of SMS-TAAT1, SMS-TAAT2, or SMS-UE-B
relieve repression of basal transcription and thus the
fold-stimulation to cAMP may be secondarily reduced.
Alternatively, it is possible that independently of their
role as negative regulators of basal transcription,
some TAAT elements may facilitate CRE-dependent
cAMP-induced transcription of the somatostatin gene
in cerebrocortex-derived cells. To further explore this
possibility, we carried out transient transfections in
RC2.E10 cells to evaluate whether the presence of
TAAT elements immediately upstream from the CRE
alters the response of SMS65 to cAMP stimulation.
Treatment of RC2.E10 cells with 8-Br-cAMP re-
sulted in a 2.8-fold increase in the CAT activity gen-
erated by SMS65 (Fig. 7). Placing either TAAT3 or
SMS-UE-B upstream from the CRE did not signifi-
cantly alter the strength of the response to 8-Br-cAMP
(2.3-fold and 2.7-fold, respectively) (Fig. 7). However,
the presence of SMS-TAAT2 resulted in a significant
increase in the fold stimulation elicited by 8-Br-cAMP
(4.6-fold, P , 0.05, Student’s t test, as compared with
SMS65). In contrast, SMS-TAAT1 inhibited cAMP-
dependent stimulation of SMS65 (Fig. 7). Thus, these
results are consistent with the notion that, whereas
TAAT1 represses both basal and cAMP-stimulated
transcription, TAAT2 represses basal transcription but
appears to facilitate cAMP-stimulated transcription.
DISCUSSION
To date, studies to identify and characterize DNA cis-
regulatory elements that participate in the control of
somatostatin gene expression have been carried out
in nonneural cells, using primarily pancreatic islet cell
lines derived from endocrine tumors (4–10, 21). In the
present study, we found evidence that in neural cells,
as in pancreatic cells, the expression of the soma-
tostatin gene appears to be regulated by the balanced
activity of both negative- and positive-acting regula-
tory elements distributed throughout the promoter re-
gion. However, the location and/or function of regula-
tory elements differ between pancreatic and neural
cells.
A progressive elevation in somatostatin CAT activity
was observed, especially in cortical RC2.E10 cells,
when the size of the promoter truncations generated
by 59-deletions increased, yielding levels of expression
significantly higher than those observed with the full-
length promoter. This was particularly evident as the
proximity of the 59-end of the remaining promoter
fragment approached position 265, immediately up-
stream of the CRE. Thus, it appears that the stepwise
removal of upstream negative modulatory elements
results in the increasing manifestation of the activity of
a strong positive regulatory element that would other-
wise remain relatively repressed to maintain appropri-
ate levels of expression. Our data identified the CRE as
the predicted strong positive regulator, not only be-
cause of its location downstream to nucleotide 265,
but also because its removal by a 59-deletion to posi-
tion 242 or by an internal 4-base deletion in the full-
length promoter results in levels of CAT activity indis-
tinguishable from background. Thus, the CRE appears
to play a pivotal role in the regulation of basal soma-
tostatin gene expression in neural cells. Studies in
pancreatic and thyroid cells indicate that the soma-
tostatin CRE recognizes a complex array of transcrip-
tion factors generating between three and seven com-
Fig. 6. Somatostatin TAAT-Containing Elements Bind Nu-
clear Proteins from Developing Rat Forebrain
A, EMSA with nuclear extracts of embryonic day 17 rat
forebrain (Brain) showing protein complexes bound to SMS-
TAAT1 or SMS-TAAT2 oligonucleotide probes. For compar-
ison, extracts prepared from RC2.E10 cells (CL) were also
assayed. Nuclear extracts were incubated in the absence (2)
or presence of competing oligonucleotides [10- or 100-fold
molar excess (103 or 1003, respectively)] of identical se-
quence to each probe, or in the presence of a nonspecific
competing (NSC) oligonucleotide of unrelated sequence
used in a 100-fold molar excess. Complexes numbered 1–3
are described and discussed in the text. B, EMSA showing
binding of nuclear proteins prepared from RC2.E10 cells (CL)
or from embryonic day 17 rat forebrain (Brain) to an oligonu-
cleotide probe corresponding to the somatostatin SMS-
UE-B. Binding reactions were carried out in the presence of
an antiserum that recognizes homeodomain-type proteins
(Anti-HD, Ref. 8) or normal rabbit serum (NRS). Arrows indi-
cate the absence of the top protein-DNA complex in the
presence of the specific antiserum.
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plexes by EMSA (4, 10, 22). We have observed a
similar degree of complexity using nuclear extracts of
RC2.E10 cells (our unpublished results), although the
identity of the proteins that mediate basal CRE-depen-
dent transcription in neural cells remains to be
determined.
No evidence of regulatory elements has previously
been reported in studies with pancreatic cells in a
distal region of the promoter spanning nucleotides
2750 to 2900. We observed that the decrease in CAT
activity after the deletion of this region was more pro-
nounced in hippocampal RH1.C4 cells (13% of
SMS900) than in cortical RC2.E10 cells (40% of
SMS900). Somatostatin message levels appeared
higher in RH1.C4 than in RC2.E10 cells, and our stud-
ies comparing the activity of SMS900 to that of RSV-
CAT suggest that the somatostatin gene is more effi-
ciently expressed in RH1.C4 than in RC2.E10 cells.
Therefore, these results suggest the existence of pos-
itive elements between 2900 and 2750 that act more
efficiently in hippocampal than in cerebrocortical cells
and thus may play a role in the control of region-
specific expression within the central nervous system.
The presence of a neuron-restricted silencer ele-
ment (NRSE) (23–29) in the promoters of certain neural
and pancreatic genes suggests a possible mechanism
for their expression both in neurons and in pancreatic
islet cells (30–32). Although the somatostatin gene
promoter does not contain an NRSE-like sequence,
our studies indicated the presence of several regions
of the somatostatin promoter that contain transcrip-
tional repressor elements. In hippocampal RH1.C4
cells, 59-deletion experiments allowed us to map the
location of these repressor elements within positions
2750 to 2550, 2345 to 2250, and 2120 to 265. In
pancreatic cells, distal negative control elements have
only been documented between nucleotides 2425
and 2345, but not upstream from that position (5).
Therefore, repressor elements located between nucle-
otides 2750 and 2550 may represent neural-specific
elements important for the modulation of adequate
levels of expression of the somatostatin gene in the
nervous system.
Notably, deletion of a region containing PS1 and
PS2, two previously identified proximal silencer ele-
ments that repress transcription in pancreatic cells,
located between nucleotides 2250 and 2120 (10), did
not result in an increase of activity in hippocampal
cells, suggesting that these elements are not active in
these cells or that this region contains additional un-
identified positive elements that offset the activity of
PS1 and PS2. However, in cerebrocortical RC2.E10
cells, PS1 and PS2 are likely to be active, because a
deletion from nucleotides 2250 to 2120 resulted in a
significant increase in CAT activity. Thus, it appears
that the region spanning nucleotides 2345 to 265
contains transcriptional repressor elements, including
SMS-TAAT2 (between 2345 and 2250), PS1 and PS2
(between 2250 and 2120), and SMS-UE-B (between
2120 and 265), which seem to be required for down-
regulation of the strong transcriptional activity elicited
by the CRE in RC2.E10 cells.
SMS-TAAT1 was found to act as a strong repressor
of CRE-dependent transcription in RC2.E10 cells.
However, our initial 59-deletion experiments did not
allow us to predict that SMS-TAAT1 would act as a
repressor, because removal of the fragment spanning
2550 to 2425 (SMS-TAAT1 is located between 2449
and 2445) resulted in decreased rather than increased
transcriptional activity. This apparent discrepancy
could be explained by the existence of two positive
regulatory elements in close proximity to SMS-TAAT1
that can provide binding sites for GATA-type tran-
scription factors (33).
The negative regulatory elements characterized in
this study, SMS-TAAT1, SMS-TAAT2, and SMS-UE-B,
Fig. 7. Effects of cAMP Stimulation on the Expression of Somatostatin CAT Reporter Plasmids after Transfections in RC2.E10
Cells
Plasmids used for transfections are identical to those depicted in Fig. 4, with the exception of SMS120, which is described in
Fig. 3. Transfected cells were treated with 8-Br-cAMP (1 mM) for 16 h before harvesting. Values are expressed as percentages
of the CAT activity elicited by SMS900 (left) or SMS65 (right) in basal conditions.
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have been previously identified in pancreatic cells as
enhancers that bind homeodomain-type transcription
factors (8, 9, 20, 21), and it is likely that in neural cells
these elements also bind homeodomain proteins. A
number of homeodomain-encoding genes, including
Isl-1, Pax-6, Pbx, and Brn-4, have been found to be
expressed in both endocrine pancreas, where some of
them regulate somatostatin gene transcription, and
brain (20, 21, 34–38). Our EMSA data suggest that a
protein with a homeodomain that resembles that of
IDX-1 protein is present in neural cells and binds to
SMS-UE-B. Although IDX-1 gene expression has been
considered to be restricted to stomach, duodenum,
and pancreas, it is possible that a gene encoding a
protein similar to IDX-1 is expressed in the central
nervous system (39). SMS-TAAT1 and SMS-TAAT2 do
not appear to bind an IDX-1-like protein. However, a
homeodomain protein related to Orthodenticle and
Pax may bind to these elements (our unpublished
observations).
It remains to be determined whether homeodomain
transcription factors that recognize TAAT elements in
neural cells act as transrepressor proteins or whether
they act as transactivators that compete for binding to
the same elements with nonhomeodomain-type re-
pressor proteins. Although many homeodomain tran-
scription factors function as transactivator proteins to
stimulate transcription of target genes, it has been
shown that a number of homeodomain proteins act as
transcriptional repressors on the promoter of neural
(40–45) as well as nonneural genes (46–48). Evidence
indicates that these proteins are composed of modular
domains, some of which mediate activation whereas
others mediate repression (46, 49–51). Thus, it ap-
pears that the overall transcriptional activity of a given
homeodomain protein is the result of unique combi-
nations of positive and negative acting regions oper-
ating according to determined molecular environ-
ments in different cell types.
It is possible that both positive- and negative-acting
transcription factors bind to TAAT-containing ele-
ments of the somatostatin promoter so that the tran-
scriptional activity imparted by these DNA-regulatory
sequences is the result of the combined effects of both
positive and negative trans-acting proteins. Thus, in
pancreatic RIN-1027-B2 cells, binding of activator ho-
meoproteins would predominate over repressor pro-
teins, whereas the opposite would occur in neural
RC2.E10 cells. Consistent with this model, our data
generated by EMSA suggest that complex 2 on SMS-
TAAT1 and SMS-TAAT2, present in nuclear extracts of
RC2.E10 cells but almost absent in those of RIN-
1027-B2 cells, may correspond to a repressor protein.
Conversely, complex 1, more prominent in RIN-
1027-B2 cells than in RC2.E10 cells, may correspond
to a transcriptional transactivator. Notably, SMS-
TAAT3 binds an additional complex (complex 4) not
detected on SMS-TAAT1 or SMS-TAAT2. Since SMS-
TAAT3 did not show a significant negative activity, it is
possible that complex 4 corresponds to a transcrip-
tional transactivator complex whose influence would
counteract the overall repressor activity of the other
complexes apparently shared with SMS-TAAT1 and
SMS-TAAT2. Nevertheless, it is also possible that
complexes with similar electrophoretic mobilities in
pancreatic and in neural cells correspond to related,
but not identical, proteins with small differences in
their amino acid sequences that could account for
their activities as activators or repressors (40, 52, 53),
or even to identical proteins that may have bimodal
properties, functioning as activators in some cell types
and as repressors in others (41, 43, 51, 54). Efforts to
elucidate the identities of the proteins that bind to
somatostatin TAAT elements are underway in our
laboratory.
That at least one of the TAAT-containing elements of
the somatostatin gene promoter characterized in the
present study is targeted by both positive and nega-
tive DNA-binding proteins is also supported by our
data on cAMP-induced somatostatin gene transcrip-
tion, which suggest that SMS-TAAT2 subserves a dual
role as a negative modulator in basal conditions and as
a positive facilitator of transcription under conditions
of cAMP-dependent stimulation. Earlier studies have
identified CREB, phosphorylated by protein kinase A
in response to cAMP, as a major transactivator of
somatostatin gene transcription in response to cAMP
stimulation. However, the somatostatin CRE can also
be recognized by other transcription factors such as
CCAAT/enhancer-binding protein-b (C/EBPb) and
C/ATF, which function as potent transactivators of
somatostatin gene transcription in basal conditions via
CREB-independent mechanisms (6). Thus, it is possi-
ble to hypothesize that positive-acting proteins bound
to SMS-TAAT2 could facilitate phospho-CREB-de-
pendent transcription via functional or physical inter-
actions with phosphorylated CREB or with certain co-
activators such as CREB-binding protein or TATA box-
associated factors. On the other hand, negative acting
SMS-TAAT2-binding proteins would interact with a
different set of CRE-binding or TATA box-associated
proteins, as it has been shown that some amino acid
sequences that act as repressor domains of home-
odomain proteins can interact with specific compo-
nents of the RNA polymerase II complex (55–57).
During development, somatostatin-expressing cells
in the central nervous system appear first in the pri-
mordium of the E14 hypothalamus, and other telence-
phalic regions are recruited later (12, 13, 15, 16). As the
central nervous system develops, somatostatin is ex-
pressed in differentiating neurons as well as in glial
cells, but the number of somatostatin-positive cells
fluctuates. Thus, in some areas the number of soma-
tostatin-positive cells increases progressively and re-
mains unchanged in the adult organism, whereas in
other regions somatostatin gene expression is tran-
sient, increasing first and then decreasing until it dis-
appears. This pattern of gene expression suggests a
developmentally regulated dynamic interplay between
positive- and negative-acting transcription factors,
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some of which may use TAAT-containing sites as cis-
acting targets. Identification of these neurally ex-
pressed transcription factors and elucidation of their
complex interactions on the somatostatin promoter
will shed light on our understanding of the molecular
mechanisms that regulate the expression of a single
gene in tissues of different embryological origins.
MATERIALS AND METHODS
Materials
DNA-modifying enzymes were purchased from New England
Biolabs (Beverly, MA), Boehringer Mannheim Biochemicals
(Indianapolis, IN), or Promega (Madison, WI). Radioactive
compounds were obtained from DuPont-New England Nu-
clear (Boston, MA). Nucleotides were purchased from Phar-
macia-LKB (Piscataway, NJ). Tissue culture media were pre-
pared by the Cell Culture Core Facility of the Reproductive
Endocrine Sciences Center at Massachusetts General Hos-
pital, and reagents were obtained from GIBCO-BRL (Grand
Island, NY). All other reagents were obtained from Sigma
Chemical Co. (St. Louis, MO).
Establishment of Immortalized Forebrain-Derived Cells
Primary cultures of cells from developing cerebral cortex and
hippocampus, two brain regions that contain somatostatin-
producing neurons (12), were prepared from E16 fetuses
removed from timed-pregnant Sprague Dawley rats. After
careful removal of the meningeal membranes, the cerebral
cortex was separated from the rest of the brain, and the
developing hippocampi were dissected as described (58).
Cells from these structures were dispersed, seeded onto
polyornithine-coated plates, and infected 24 h later by a
replication-defective recombinant retrovirus derived from the
Moloney murine leukemia virus that contains a neomycin-
resistant gene and an SV40T oncogene encoding tsA58/U19,
a temperature-sensitive mutant allele (17, 18). Retroviral par-
ticles (titer 105 cfu/ml) were produced by a C-2 packaging
fibroblast cell line (F4 subclone, kindly provided by Dr. G.
Almazan, McGill University, Montreal, Quebec, Canada). Ret-
rovirus-containing conditioned medium from C-2 cells was
applied directly onto primary cultured cells in the presence of
8 mg/ml polybrene (Sigma). Cells were incubated at 33 C in
DMEM supplemented with 10% FBS in the presence of the
neomycin analog G418 (GIBCO Laboratories, Grand Island,
NY). Resistant colonies appeared 3–5 weeks later and were
individually picked using cloning rings and expanded. After
five to six passages, a fraction of cells from each colony was
frozen in liquid nitrogen.
Rat islet somatostatin-producing RIN-1027-B2 (59) cells
were grown in DMEM supplemented with 10% FBS. All cell
lines were cultured in the presence of penicillin (100 U/ml)
and streptomycin (10 mg/ml).
RT-PCR, Immunocytochemistry, and RIA
Total RNA (10 mg) purified by CsCl gradient centrifugation
from individual cell lines was primed with poly-(dT)15 and
incubated with avian myeloblastosis virus (AMV) reverse tran-
scriptase (Boehringer Mannheim Biochemicals) to synthesize
cDNA. For PCR amplification, a forward primer that anneals
to the 59-untranslated region (59-GACCCACCGCGCT-
CAAGCTCGGCTG-39) and a reverse primer that anneals to
the 39-end of the coding region of exon 2 (59-AACAGGAT-
GTGAATGTCTTCCAGAA-39) of the rat somatostatin gene
(60) were used. PCR conditions were: 95 C for 5 min, followed
by 30 cycles of 94 C for 30 sec, 50 C for 30 sec, and 72 C for
1 min, after which a 5-min incubation at 72 C followed. After
PCR, an aliquot of the reaction was resolved in a 1% agarose
gel, blotted onto a nylon membrane, probed with a 32P-
labeled internal primer that anneals to the 59-region of exon 2
of the somatostatin gene (59-TTCGAGTTGGCAGACCTCTG-
CAGCTCCAGCCT-39), and autoradiographed at 270 C.
For immunocytochemistry, cells were plated into “Lab-
Tek” culture chambers (Nunc Inc., Naperville, IL), fixed in 4%
paraformaldehyde in PBS for 5 min, washed in PBS, and
permeabilized with methanol for 2 min at 220 C. After block-
ing with normal goat serum, cells were incubated overnight
with either normal rabbit serum or with a somatostatin-spe-
cific polyclonal antiserum (INCSTAR Co., Stillwater, MN) at
1:500 dilution. Immunodetection was carried out with a sec-
ondary biotinylated goat antirabbit antiserum (Bio-Rad Lab-
oratories, Hercules, CA) using immunoperoxidase staining
with a Vectastain ABC kit (Vector Laboratories, Burlingame,
CA).
For RIA, cells growing in 35-mm dishes were scraped in 2
M acetic acid and boiled for 5 min. After centrifugation, the
supernatant was collected, adjusted to pH 7.5, and lyophi-
lized. Somatostatin content in these samples was determined
by RIA using an antiserum (dilution 1:75,000) generated in
sheep against synthetic somatostatin as described (61). For
iodination, 100 pmol Tyr1-somatostatin (Sigma) was reacted
with 1 mCi [125I]sodium iodide (DuPont-New England Nu-
clear) using the method described by Greenwood et al. (62).
The minimum detectable concentration was 7.8 pg/ml.
Western Immunoblots
RH1.C4 or RC2.E10 cells were plated in duplicate 35-mm
dishes at a density of 25 3 104 or 15 3 104 cells per dish,
respectively. After an overnight incubation at 33 C, half of the
plates were transferred to a 39 C tissue culture incubator, and
incubations at both 33 C and 39 C proceeded for an addi-
tional 24 h. Cells were then lysed in buffer containing 125 mM
Tris-HCl (pH 6.8), 4% SDS, 15% glycerol, 10% b-mercapto-
ethanol, and 10 mM dithiothreitol. Proteins were resolved by
SDS-PAGE and blotted onto a nitrocellulose membrane.
SV40T immunoreactivity was detected with a monoclonal
primary antibody (1:1000 dilution) (Calbiochem, La Jolla, CA)
and a horse antimouse peroxidase-conjugated secondary
antibody (1:5000 dilution) (Bio-Rad). CREB immunoreactivity
was detected with a polyclonal primary antiserum (1:500
dilution) (Santa Cruz Biotechnology, Santa Cruz, CA) and a
goat antirabbit peroxidase-conjugated secondary antibody
(1:20,000 dilution) (Bio-Rad). Immunoreactive bands were
visualized using an enhanced chemiluminescence detection
system (Amersham, Buckinghamshire, U.K.).
Plasmid Constructions
The plasmid SMS550 was constructed using DNA fragments
obtained by PCR amplification of somatostatin gene se-
quences in the plasmid SMS900 (4). The upstream amplimers
incorporated a BamHI restriction site in its 59-end. The down-
stream amplimer annealed to the sequence corresponding to
the XbaI site at position 154. The resulting fragment was
digested with the appropriate restriction enzymes, purified on
an agarose gel, and ligated into the promoterless plasmid
pOCAT (63) that had been digested with BamHI and XbaI. All
other CAT reporter plasmids bearing 59-deletions of the so-
matostatin promoter have been described previously (4, 5).
The plasmid SMS900DCRE was constructed by ligating a
BamHI-BglII fragment obtained from SMS900 into the BamHI
site of plasmid SMS65DCRE (5). The resulting plasmid,
SMS900DCRE, preserves all the somatostatin gene se-
quences from positions 2900 to 154, with the exception of
a 4-base deletion within the core CRE motif.
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Plasmids SMS900T1M, SMS900T2M, and SMS900UEBM
have been described previously (8). Plasmid SMS900T3M
was constructed by oligonucleotide-directed mutagenesis
using a DNA fragment obtained by PCR amplification of
somatostatin sequences in plasmid SMS900. The upstream
amplimer anneals to a sequence located immediately up-
stream of the BamHI site of SMS900. The downstream am-
plimer was designed to anneal to a region of the somatostatin
promoter spanning nucleotides 2377 to 2341, which con-
tains the SMS-TAAT3 sequence located upstream of a KpnI
site. This primer contained a six-base mismatch to replace
the sequence 59-GTAATC-39 by 59-ACGGCT-39, a similar
change to the ones introduced in SMS-TAAT1, SMS-TAAT2,
and SMS-UE-B (8). Reduced binding of nuclear proteins to
the mutated SMS-TAAT3 sequence was confirmed by EMSA
using synthetic oligonucleotides (data not shown). After PCR
amplification and restriction enzyme digestion, this fragment
was used to replace the wild-type fragment located between
BamHI and KpnI in SMS900.
For the construction of T3SMS65, a synthetic double-
stranded oligonucleotide corresponding to SMS-TAAT3 (nu-
cleotides 2377 to 2355) with BamHI and BglII sites at the 59-
and 39-ends, respectively, was ligated into the BamHI site of
the plasmid SMS65 (4). The sequence of this oligonucleotide
is (coding strand): 59-GATCCAAGTCCAGTAATCTGAGT-
ACAT-39.
The correct sequence of all the newly made plasmids was
verified by the enzymatic procedure (Sequenase, United
States Biochemical Corp., Cleveland, OH).
Transfections and CAT Assays
Initially, DNA transfections of neural cells were tested using
three different methodologies: a modified diethylaminoethyl-
dextran procedure (5), a calcium phosphate-DNA coprecipi-
tation method, and lipofectin (GIBCO Laboratories, Grand
Island, NY). Two different CAT reporter plasmids were used in
parallel experiments, one under the control of the b-actin
promoter (a gift of Dr. William Walker, University of Pitts-
burgh), and another under the control of the Rous sarcoma
virus (RSV) enhancer. The diethylaminoethyl-dextran proce-
dure was found to yield very low levels of CAT activity and
was discarded. The calcium phosphate-DNA coprecipitation
method yielded adequate levels of reporter plasmid expres-
sion, and b-actin-CAT was found to exhibit levels of CAT
activity higher than those of RSVCAT. However, the b-actin-
CAT/RSVCAT activity ratio was highly variable from experi-
ment to experiment, a likely reflection that transfection effi-
ciencies were not uniform. In contrast, when lipofectin was
used, b-actin-CAT was consistently found to be 8 to 10 times
more potent than RSVCAT (observed in at least five indepen-
dent experiments carried out in duplicate). This information
was used as an indication that transfection efficiencies were
relatively uniform among different dishes in each experiment.
This was confirmed in a different set of experiments in which
cells were stained for b-galactosidase after transfection of a
plasmid bearing an RSV-b-galactosidase fusion gene.
RH1.C4 and RC2.E10 cells were transfected with lipofectin
following instructions provided by the manufacturer. Cells
growing as monolayers up to 80% confluency were
trypsinized and plated at a density of 5 3 105 cells per 60-mm
plate. After an overnight incubation, 20 mg of reporter plasmid
DNA mixed with lipofectin were added to the cells in 1 ml
serum-free DMEM and incubated for 4 h. After this, 3 ml
DMEM supplemented with 10% FBS was added. CAT activ-
ity was measured by a solution assay (64) 48 h after trans-
fection. For cAMP-induction studies, 8-Br-cAMP was added
to cells 16 h before harvesting. All the values are expressed
as mean 6 SEM of at least three independent experiments
carried out in duplicate.
DNA Protein-Binding Assays
EMSAs were carried out with nuclear extracts (65), in the
presence of the protease inhibitors pepstatin A (1 mg/ml),
leupeptin (10 mg/ml), aprotinin (10 mg/ml), and p-aminoben-
zamidine (0.1 mM). Protein concentrations were determined
by the Bio-Rad protein assay with BSA as a standard. Syn-
thetic complementary oligonucleotides with 59-GATC over-
hangs were annealed and labeled by a fill-in reaction using
a-32P-dATP and Klenow enzyme. Binding reactions were
carried out in the presence of 2 mg of poly(deoxyinosinic-
deoxycytidylic)acid, and specific competitors, as indicated,
using nuclear extracts (10 mg protein) incubated with 20,000
cpm of radiolabeled probe (;6–10 fmol) in a total volume of
20 ml containing 20 mM potassium phosphate (pH 7.9), 70 mM
KCl, 1 mM dithiothreitol, 0.3 mM EDTA, and 10% glycerol. The
sequences of the oligonucleotides corresponding to SMS-
TAAT1, SMS-TAAT2, SMS-UE-B, and nonspecific competi-
tor have been published previously (6–8). The sequence of
the SMS-TAAT3 oligonucleotide is identical to the one used
to construct the plasmid T3SMS65 (see above).
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